An experimental molecular therapy restores insulation on peripheral nerves in mice, shows study by a research team at the Cincinnati Children's Hospital Medical Center. The therapy was found to improve limb function, and resulted in less observable discomfort. The study is published in Nature Medicine.
When the body attacks its own healthy tissues in an autoimmune disease, peripheral nerve damage handicaps people and causes persistent neuropathic pain when insulation on healing nerves doesn't fully regenerate. This layer of insulation on nerve cells is called the myelin sheath. Unfortunately, there are no effective ways to treat the condition.
A Supplement for Regeneration of Myelin Sheath in Multiple Sclerosis Patients
Multiple sclerosis patients continually lose the insulating myelin sheath that wraps around neurons and increases the speed of impulses in the central nervous system.
Advertisement
‘Inhibiting an enzyme called HDAC3 in mice increased the expansion of schwann cells which form the protective insulating layer of nerve cells called myelin.’
Tweet it Now
To identify possible therapies, the international team of investigators performed small-molecule epigenetic screening for compounds that inhibit enzymes involved in epigenetic changes on chromosomes. These changes alter how gene activity in cells is regulated. The authors identified small molecular inhibitors already used to treat certain cancers and tested them in experimental treatments on mice with injured sciatic nerves.
The molecular compounds target the enzyme HDAC3 (histone deacetylase 3). Study data show that HDAC3 inhibits regenerating insulation on recovering peripheral nerves.
![Fat Metabolism Inhibits Regeneration in Central Nervous System]( "Fat Metabolism Inhibits Regeneration in Central Nervous System")
Cholesterol crystals formed from myelin sheaths are not completely destroyed by phagocytes that lead to degeneration of myelin sheaths in multiple sclerosis.
"Remarkably, temporary inhibition of HDAC3 robustly accelerated the formation of myelin that helps insulate peripheral nerves," says the study's principal investigator Q. Richard Lu, PhD, director of the Cincinnati Children's Brain Tumor Center. "This promoted functional recovery in the animals after peripheral nerve injury."
Restoring Signal Relays
The peripheral nervous system relays signals from the brain and spinal cord (the central nervous system) to limbs and organs. HDAC3 is an enzyme found in humans and mice. Its usual job in peripheral nerve formation is to act as a molecular brake on the production of the myelin coating by Schwann cells.
After peripheral nerve injury, HDAC3 initiates epigenetic changes to chromosomes and gene regulation that excessively restrict myelin regeneration. This results in nerve insulation that is too thin or not totally formed, blocking or slowing signals between the spinal cord, extremities and organs.
Timing is Crucial
Researchers carefully timed their targeted treatments when inhibiting HDAC3, treating the mouse models of nerve injury only during a critical phase of nerve regeneration. This resulted in the right amount of re-myelination to restore normal function in the animals.
Getting the timing right on transient treatment is critical, Lu says. Researchers show that blocking HDAC3 for too long allows myelin to overgrow and cause excessively thick insulation. This also can lead to functional problems in extremities, according to study data.
From Science to Medicine
Translating data in the current study to clinical application in human patients will require extensive additional research, Lu says. Now that the prospective therapy has been successfully tested in mice, researchers are exploring additional research in animal models that more closely mimic the repair of injured peripheral nerves in people. This includes looking specifically at some demyelinating diseases that affect the central nervous system, such as multiple sclerosis.
Lu said this work will allow scientists to replicate and verify their findings in mice and other laboratory models. They also will be able to test possible dosing levels. If results are positive, Lu said researchers could pursue possible Phase I clinical trials in patients having deficient myelin in their peripheral and central nervous systems.
Source: Eurekalert
Fat Metabolism Inhibits Regeneration in Central Nervous System
Cholesterol crystals formed from myelin sheaths are not completely destroyed by phagocytes that lead to degeneration of myelin sheaths in multiple sclerosis.
Advertisement
"Remarkably, temporary inhibition of HDAC3 robustly accelerated the formation of myelin that helps insulate peripheral nerves," says the study's principal investigator Q. Richard Lu, PhD, director of the Cincinnati Children's Brain Tumor Center. "This promoted functional recovery in the animals after peripheral nerve injury."
Restoring Signal Relays
The peripheral nervous system relays signals from the brain and spinal cord (the central nervous system) to limbs and organs. HDAC3 is an enzyme found in humans and mice. Its usual job in peripheral nerve formation is to act as a molecular brake on the production of the myelin coating by Schwann cells.
After peripheral nerve injury, HDAC3 initiates epigenetic changes to chromosomes and gene regulation that excessively restrict myelin regeneration. This results in nerve insulation that is too thin or not totally formed, blocking or slowing signals between the spinal cord, extremities and organs.
Timing is Crucial
Researchers carefully timed their targeted treatments when inhibiting HDAC3, treating the mouse models of nerve injury only during a critical phase of nerve regeneration. This resulted in the right amount of re-myelination to restore normal function in the animals.
Getting the timing right on transient treatment is critical, Lu says. Researchers show that blocking HDAC3 for too long allows myelin to overgrow and cause excessively thick insulation. This also can lead to functional problems in extremities, according to study data.
From Science to Medicine
Translating data in the current study to clinical application in human patients will require extensive additional research, Lu says. Now that the prospective therapy has been successfully tested in mice, researchers are exploring additional research in animal models that more closely mimic the repair of injured peripheral nerves in people. This includes looking specifically at some demyelinating diseases that affect the central nervous system, such as multiple sclerosis.
Lu said this work will allow scientists to replicate and verify their findings in mice and other laboratory models. They also will be able to test possible dosing levels. If results are positive, Lu said researchers could pursue possible Phase I clinical trials in patients having deficient myelin in their peripheral and central nervous systems.
Source: Eurekalert
Blood Clotting Factor in the Brain Halts Myelin Repair
Blood clotting factor stops stem cells in the brain from producing myelin, and disrupts myelin repair in nervous system diseases, says study.
Advertisement
Why Some Patients With Multiple Sclerosis Develop Seizures?Multiple sclerosis is an autoimmune disease of the central nervous system that affects nearly 2.3 million people worldwide. | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
New study sheds light on the intrinsic, yet often overlooked, role of sleep preparation as a hardwired survival strategy.
Microgravity-induced bone loss in space, can be reduced by systemic delivery of NELL-1, a protein required for bone growth and its maintenance.
Researchers establish connections between Alzheimer's-linked genetic alterations and the functioning of brain cells.
Team at NeuroRestore introduces a groundbreaking gene therapy that has effectively promoted nerve regrowth and reconnection, post spinal cord injury.
Scientists aim to pinpoint particular functional pathways affected by these bacteria that may have an impact on skeletal health.
